García-González Nerea, Gonçalves-Sánchez Jaime, Gómez-Nieto Ricardo, Gonçalves-Estella Jesús M, López Dolores E
Institute of Neuroscience of Castilla y León, 37007 Salamanca, Spain.
Department of Cellular Biology and Pathology, School of Medicine, University of Salamanca, 37007 Salamanca, Spain.
Int J Mol Sci. 2024 Nov 21;25(23):12485. doi: 10.3390/ijms252312485.
This review explores recent advancements in gene therapy as a potential treatment for neurodegenerative diseases, focusing on intervention mechanisms, administration routes, and associated limitations. Following the PRISMA procedure guidelines, we systematically analyzed studies published since 2020 using the PICO framework to derive reliable conclusions. The efficacy of various gene therapies was evaluated for Parkinson's disease (n = 12), spinal muscular atrophy (n = 8), Huntington's disease (n = 3), Alzheimer's disease (n = 3), and amyotrophic lateral sclerosis (n = 6). For each condition, we assessed the therapeutic approach, curative or disease-modifying potential, delivery methods, advantages, drawbacks, and side effects. Results indicate that gene therapies targeting specific genes are particularly effective in monogenic disorders, with promising clinical outcomes expected in the near future. In contrast, in polygenic diseases, therapies primarily aim to promote cell survival. A major challenge remains: the translation of animal model success to human clinical application. Additionally, while intracerebral delivery methods enhance therapeutic efficacy, they are highly invasive. Despite these hurdles, gene therapy represents a promising frontier in the treatment of neurodegenerative diseases, underscoring the need for continued research to refine and personalize treatments for each condition.
本综述探讨了基因治疗作为神经退行性疾病潜在治疗方法的最新进展,重点关注干预机制、给药途径及相关局限性。遵循PRISMA程序指南,我们使用PICO框架系统分析了自2020年以来发表的研究,以得出可靠结论。评估了各种基因疗法对帕金森病(n = 12)、脊髓性肌萎缩症(n = 8)、亨廷顿病(n = 3)、阿尔茨海默病(n = 3)和肌萎缩侧索硬化症(n = 6)的疗效。对于每种疾病,我们评估了治疗方法、治愈或改善疾病的潜力、递送方法、优点、缺点和副作用。结果表明,针对特定基因的基因疗法在单基因疾病中特别有效,预计在不久的将来会有有前景的临床结果。相比之下,在多基因疾病中,治疗主要旨在促进细胞存活。一个主要挑战仍然存在:将动物模型的成功转化为人类临床应用。此外,虽然脑内递送方法可提高治疗效果,但它们具有高度侵入性。尽管存在这些障碍,基因治疗仍是神经退行性疾病治疗中一个有前景的领域,这突出表明需要继续开展研究,以针对每种疾病优化治疗方法并实现个性化治疗。